Valeant Pharmaceuticals International Inc (NYSE:VRX)(TSX:VRX) stated on Thursday that it plans to pay down another USD200m of its senior secured term loans with cash on hand.
Following the repayment of debt next week, the company will have reduced its debt, in aggregate, by more than USD6.7bn since the end of Q1 2016.
In conjunction, the company's total long-term debt will be about USD25.5bn.
The specialist pharmaceutical company develops, manufactures and markets a broad range of pharmaceutical products in dermatology, gastrointestinal disorders, eye health, neurology and branded generics.
Fresenius Kabi Introduces Leucovorin Calcium Injection, USP
FDA Approves Dr. Reddy's Tosymra 10 mg, in the US Market
Dr. Reddy's Laboratories Announces the Launch of Propofol Injectable Emulsion, USP in the US Market
Amerigen awarded US FDA's approval for generic mixed amphetamine salts, extended-release capsules
Pharmaceutics International names new president and CEO
Amneal wins US FDA approval for Rivastigmine Transdermal System
Premier Expands Effort to Supply Shortage Generic Drugs
Ferring Pharmaceuticals Adds Two Products to its Reproductive Health Portfolio in the US
China's Bio-Thera Solutions Partners with Cipla to Market Key Cancer Biosimilar
EpicGenetics Moves into New Facility, Expanding Capacity by 4X
Amneal Pharmaceuticals appoints David A. Buchen as SVP, chief legal officer and corporate secretary
Ironwood Pharmaceuticals and Allergan reach agreement to resolve Mylan LINZESS patent litigation
Teva and Amgen Resolve Ongoing Dispute Over Teva's Generic Cinacalet HCl Product